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Human immunodeﬁciency virus (HIV) infection during pregnancy
induces CD4 T-cell differentiation and modulates responses to
Bacille Calmette-Gue ´rin (BCG) vaccine in HIV-uninfected infants
Introduction
Over 35 million women of childbearing age are infected
annually with human immunodeﬁciency virus (HIV) in
Sub-Saharan Africa,
1 and large numbers of children are
born to HIV-positive women. Infants infected in utero or
perinatally have a poor prognosis, with as many as 25%
developing acquired immune deﬁciency syndrome (AIDS)
within the ﬁrst year.
2 However, even in the absence of
interventions such as antiretroviral therapy (ART) or cae-
sarean section, most infants born to HIV-positive women
are not infected. The rapidly expanding availability of
ART to prevent perinatal transmission throughout Africa
makes it likely that the overwhelming majority of infants
born to HIV-positive mothers will remain HIV-negative.
These ‘seroreverters’
3 are born with maternally derived
antibodies to HIV that they later lose. They frequently
have lower birth weights than infants born to HIV-
negative mothers,
4 and a low maternal CD4 count was
found to be a strong risk factor for infant mortality and
hospital admission in this infant population.
5
The implication that seroreverters are physiologically
and immunologically disadvantaged is supported by their
lower CD4 counts and higher proportions of differentiated
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Summary
Human immunodeﬁciency virus (HIV)-negative infants born to HIV-
positive mothers frequently exhibit a range of immunological abnormali-
ties. We tested the hypothesis that HIV during pregnancy affects the
ability of CD4 T cells of HIV-negative infants to respond to vaccine chal-
lenge by recruiting HIV-negative infants born to HIV-negative and
HIV-positive mothers and measuring their responses to Bacille Calmette-
Gue ´rin (BCG) vaccine given at birth. At 2 weeks, maternal HIV status did
not inﬂuence CD4 T-cell counts or differentiation, but by 10 weeks CD4
counts of infants born to HIV-positive mothers fell to a level characteris-
tic of HIV-positive infants. Among the CD4 T-cell populations, markers
of differentiation (CCR7
) CD45RA
) CD27
)) and senescence (CD57,
PD-1) were more common among infants born to HIV-positive mothers
than among infants born to HIV-negative mothers. At 2 weeks of age, we
assessed the effector response to heat-killed BCG and tuberculin puriﬁed
protein derivative (PPD) by overnight interferon (IFN)-c enzyme-linked
immunosorbent spot-forming cell assay (ELISpot), but found no measur-
able effect of maternal HIV status. At 10 weeks, we assessed CD4 T-cell
memory by measuring proliferation in response to the same antigens. We
observed a bimodal response that allowed infants to be classiﬁed as high
or low responders and found that fewer infants born to HIV-positive
mothers were able to mount a robust proliferative response, suggesting
that their reduced CD4 counts and increased differentiation indicated a
deﬁciency in their ability to develop immunological memory.
Keywords: Bacille Calmette-Gue ´rin (BCG); CD4
+ T lymphocytes; human
immunodeﬁciency virus (HIV); immunological memory; infant
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3,6,7 than infants born to HIV-negative mothers.
As low CD4 counts and large differentiated T-cell subpopu-
lations are associated with reduced immune responses in
the context of HIV infection
8–10 and aging,
11,12 it is consis-
tent that seroreverters also show relatively poor interleukin
(IL)-2
6 and IL-12
13 production in response to polyclonal
stimuli.
Impairment of seroreverters’ immune systems is of par-
ticular concern in Sub-Saharan Africa, which has both a
high HIV prevalence and a high burden of infectious dis-
ease.
14 Immune impairment suggests a mechanism for the
frequent poor health of seroreverters
5,15 but no conclu-
sion can be drawn without establishing whether the
impairment affects antigen-speciﬁc responses and the
development of immune memory to natural infectious
challenge or vaccination.
One of the most widely used vaccines world-wide is the
Bacille Calmette-Gue ´rin (BCG) strain of Mycobacterium
bovis, which protects against miliary tuberculosis and
tuberculosis meningitis in childhood.
16 BCG is given at
birth in most African countries and induces a strong cel-
lular response, especially in CD4 T cells.
17,18 Thus BCG
represents a robust model for assessing antigen-speciﬁc
CD4 T-cell responses in infants.
We therefore tested the hypothesis that HIV during
pregnancy reduces CD4 T-cell responses in healthy infants
by comparing the development of immunity to BCG
between seroreverters and a control group born to HIV-
negative mothers. We administered the BCG vaccine at
birth and assessed the T-cell effector response at 2 weeks
and the T-cell memory response at 10 weeks, while quan-
tifying CD4 T-cell subpopulations at both time-points. At
2 weeks of age, we found no discernable differences in
CD4 T-cell subpopulations or the effector response to
BCG. However, by 10 weeks, seroreverters had lower CD4
counts, higher levels of CD4 T-cell differentiation and
reduced proliferative capacity in response to mycobacte-
rial antigens. Together these data indicate an impaired
ability to both induce CD4 T-cell differentiation and
stimulate a pool of memory T cells through vaccination.
Methods
Recruitment and immunization
Women with known HIV status were asked to provide
informed consent and were recruited when they gave
birth at Queen Elizabeth Central Hospital (QECH), Blan-
tyre. The exclusion criteria were any serious complication
during pregnancy or delivery, and infants that had birth
weights of below 2 kg or required emergency postnatal
care. All HIV-positive mothers were given 200 mg nevira-
pine during labour and their infants were given 2 mg/kg
nevirapine within 72 hr post-partum according to
national guidelines.
19
Neonates were weighed and measured at birth and
APGAR scores (a standard measure of neonatal health
with a range from one to ten, was recorded at 1 min and
5 min after delivery) were recorded. Basic socioeconomic
information was collected from their mothers.
The protocol was approved by the University of Mala-
wi’s College of Medicine Research and Ethics Committee
and the Liverpool School of Tropical Medicine’s Research
Ethics Committee.
Vaccine preparations
Infants were vaccinated at birth with oral trivalent polio-
myelitis vaccine (OPV) (Sanoﬁ-Pasteur) and BCG. The
BCG was Danish strain 1331 at 1–4 · 10
5 colony-forming
units (cfu) per dose (Statens Serum Institute, Copenha-
gen, Denmark).
For the assays, heat-killed BCG was prepared by heat-
inactivating the contents of one vial (2–8 · 10
6 cfu) at
80  for 20 min
20 and conﬁrming inactivation by establish-
ing no growth after 10 weeks on Lo ¨wenstein–Jensen med-
ium (E&O Laboratories, Bonnybridge, UK). As each vial
also contained 375 mg of sodium glutamate, a negative
control solution containing an equivalent concentration
was also prepared.
Sampling schedule and HIV diagnosis
At birth, a sample of umbilical cord blood serum was col-
lected and stored. When the infant reached 2 weeks of
age, a venous blood sample was collected into heparin.
For the enzyme-linked immunosorbent spot-forming cell
assay (ELISpot), peripheral blood mononuclear cells
(PBMCs) were isolated using lymphoprep (Axis-Shield,
Dundee, UK). At 10 weeks, a second sample was taken
and PBMCs were collected for the proliferation assay if
sufﬁcient numbers were isolated. If the mother was HIV-
positive, 05 ml of the sample was collected into ethylen-
ediaminetetraacetic acid (EDTA) and used to diagnose
the infant’s HIV status using the Amplicor PCR kit
(Roche, Basel, Switzerland). Infected infants were referred
for further clinical management at QECH.
CD4 T-cell subpopulations
Lymphocytes were enumerated with an HmX haematology
analyser (Beckman-Coulter, Fullerton, CA). The CD4 T
cells and their subpopulations were identiﬁed by ﬂow
cytometry, for which all reagents and equipment were
from Becton Dickinson (Franklin Lakes, NJ) unless other-
wise speciﬁed. The CD4 T cells were identiﬁed by staining
with PerCP-labelled CD4 and subpopulations were fur-
ther characterized using a panel of ﬂuorescein isothiocya-
nate (FITC)-labelled anti-PD-1 (eBioscience, San Diego,
CA) and anti-CD57, phycoerythrin (PE)-labelled anti-
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anti-CD27 and Alexa Fluor 647-labelled anti-CCR7 anti-
bodies. Erythrocytes were lysed using FACSlyse.
The samples were acquired on a FACSCalibur using
CELLQUEST PRO software (Becton Dickinson) and data were
analysed with FLOWJO 7.2.2 for Windows (Treestar, Ash-
land, OR). Concentrations of subpopulations in periph-
eral blood were calculated by multiplying the percentage
of lymphocytes within each subpopulation by the lym-
phocyte count.
ELISpot
The assay was carried out on 96-well plates with polyviny-
lidene diﬂuoride (PVDF)-based wells (Millipore, Billerica,
MA). The PBMCs were resuspended in R10F [90% v/v
RPMI-1640 containing 100 U/ml penicillin, 100 lg/ml
streptomycin and 2 mML -glutamine, and 10% v/v fetal
bovine serum (FBS)] and 2 · 10
5 PBMCs were placed in
each well of the plate. All wells were costimulated with
antibodies to CD28 and CD49d (Becton Dickinson), and
duplicate wells were stimulated with 10 lg/ml tuberculin
puriﬁed protein derivative RT50 (PPD) (Statens Serum
Institute), heat-killed BCG at a ﬁnal dilution of 1 : 1500,
negative control solution or 20 lg/ml phytohaemagglutinin
(PHA).
After 18 hr at 37  in 5% CO2, interferon (IFN)-c-pro-
ducing cells were quantiﬁed using monoclonal antibodies
(Mabtech, Nacka Strand, Sweden) and an alkaline phospha-
tase detection system (Bio-Rad, Hercules, CA). Spots were
counted using an ELRO4 ELISpot reader with ELISPOT reader
version 4.0 software (AID, Straßberg, Germany). Results are
expressedasspeciﬁcspot-formingunits(SFU),calculatedby
subtracting the mean negative control count from the count
foreachtreatmentandexpressedper10
6cells.
Proliferation assay
Cells were labelled with 250 nM carboxyﬂuorescein diace-
tate succinimidyl ester (CFSE) (Invitrogen, Carlsbad, CA)
as previously described
21 and resuspended at 2 · 10
6
PBMCs/ml in R10AB [90% v/v RPMI-1640 (Sigma, St
Louis, MO) containing 100 U/ml penicillin (Sigma),
100 lg/ml streptomycin (Sigma) and 2 mML -glutamine
(Sigma), and 10% v/v human serum (Sigma)].
Cells were costimulated with antibodies to CD28 and
CD49d (Becton Dickinson), and treated with either
25 lg/ml PPD, a 1 : 100 dilution of heat-inactivated
BCG, negative control solution with a ﬁnal concentration
of 375 lg/ml sodium glutamate or 2 lg/ml PHA.
Cells were incubated for 8 days at 37  with a 5% CO2
atmosphere before being harvested and stained with
PerCP-conjugated anti-CD3, PE-conjugated anti-CD8 and
APC-conjugated anti-CD4 antibodies (Becton Dickinson)
and analysed as before by ﬂow cytometry.
Assessment of antibody responses
Antibody levels in umbilical cord blood serum and hepa-
rinized plasma collected at 10 weeks of age were assessed by
enzyme-linked immunosorbent assays (ELISAs) detecting
immunoglobulin G (IgG) to Mycobacterium tuberculosis
(Demeditec, Kiel-Wellsee, Germany) and polio (IBL-Ham-
burg, Hamburg, Germany).
Statistical analysis
All statistical analyses were restricted to infants who
remained HIV-negative throughout the course of the study.
Subpopulation sizes and ELISpot responses were compared
by Mann–Whitney U-test. Proliferation data were assessed
by dividing subjects into those with high and low levels of
division and comparing by Yates-corrected chi-squared
test. Differences in growth were assessed by analysis of
covariance (ANCOVA) in which the equivalent parameters at
birth were used as a covariate. Levels of anti-M. tuberculosis
and anti-polio IgG at 10 weeks were assessed by ANCOVA
with the equivalent levels of IgG in umbilical cord blood as
a covariate. Differences were considered signiﬁcant when
P <0 05. The analysis was carried out using STATA 8.0
(Statacorp, College Station, TX) and MINITAB 15 (Minitab
Inc., Coventry, UK).
Results
Cohort characteristics
All pregnancies were full term and both pregnancies and
deliveries were uncomplicated. The 16 HIV-positive and 21
HIV-negative mothers were similar in terms of the socio-
economic parameters recorded. Ages were similar [median
23 years (interquartile range (IQR) 200–260 years) for
HIV-negative mothers versus 24 years (IQR 225–275
years) for HIV-positive mothers], as were lengths of time at
school [median 90 years (IQR 70–100 years) for HIV-
negative mothers versus 75 years (IQR 28–108 years) for
HIV-positive mothers]. All 21 HIV-negative mothers who
gave information were married, while 10 of 13 HIV-posi-
tive mothers (77%) were married.
Three infants born to HIV-positive mothers were diag-
nosed with HIV infection and the remainder tested nega-
tive and were classiﬁed as seroreverters. The few data
from the three HIV-positive infants showed high variance
and revealed no clear trends, so they were excluded from
all further analyses (data not shown).
At birth, seroreverters tended towards smaller sizes and
lower weights, although the difference was only statisti-
cally signiﬁcant for mid-upper arm circumference
(MUAC) (Table 1). While infants born to HIV-positive
mothers tended to have slightly lower APGAR scores at
1 min, all but two infants had maximal APGAR scores of
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growth during the 10 weeks of the study based on
changes in weight, length, head circumference or MUAC
(data not shown).
Infants born to HIV-positive mothers had reduced
CD4 counts and more differentiated CD4 T cells by
10 weeks of age
At 2 weeks of age, maternal HIV status had no discernable
effect on the infants’ CD4 counts, but by 10 weeks of age,
the CD4 counts of seroreverters had dropped below those
of infants born to HIV-negative mothers in terms of both
concentration in peripheral blood (P =0 041) and percent-
age of total lymphocytes (P =0 024) (Table 1).
Based on CD45RA and CCR7 expression, CD4 T cells
may be classiﬁed as naı ¨ve (CCR7
+ CD45RA
+), central
memory (CCR7
+ CD45RA
)), effector or effector memory
(CCR7
) CD45RA
)) and effector memory RA
(CCR7
) CD45RA
+) cells.
22–24 Maternal HIV status did
not inﬂuence concentrations or relative proportions of
the four subpopulations at 2 weeks of age. However, by
10 weeks, the concentrations of naı ¨ve and central memory
cells in seroreverters had fallen substantially, indicating
that the loss of CD4 T cells occurred mainly among the
less differentiated subsets (Fig. 1a,b).
As CD4 T cells differentiate, they lose expression of
CD27 and then CD28, allowing classiﬁcation into early
(CD27
+ CD28
+), intermediate (CD27
) CD28
+) or late
(CD27
) CD28
)) differentiated subpopulations.
12,25 At
2 weeks, seroreverters had slightly fewer early differenti-
ated and more intermediate CD4 T cells than infants
born to HIV-negative mothers. This difference increased
by 10 weeks (Fig. 1c,d). Fully differentiated cells were
infrequent at both time-points. The same trends were evi-
dent whether the analysis was based on the cell concen-
tration in peripheral blood or proportions of the total
CD4 T-cell population (data not shown).
Surface expression of CD57
26 or PD-1
27,28 has been
associated with replicative senescence in CD4 T cells, and
by 10 weeks of age, expression of both was more frequent
on the CD4 T cells of seroreverters (Fig. 2).
Both markers tended to be more prevalent among dif-
ferentiated cells of seroreverters. In particular, CD57 was
considerably more prevalent among the effector memory
(CCR7
) CD45RA
)) subpopulation (P =0 017) of sero-
reverters than in that of infants with HIV-negative
mothers, and PD-1 was more prevalent among the fully
differentiated (CD27
) CD28
)) subpopulation (P =0 026)
of seroreverters (data not shown).
HIV infection during pregnancy did not inﬂuence
infant effector responses to BCG at 2 weeks
BCG vaccination rapidly induces a large population of
IFN-c-producing T cells,
17,18,29 so the effector response was
evaluated by assessing the ex vivo IFN-c response to PPD
and heat-killed BCG at 2 weeks. Background responses,
measured in negative control wells, were similar, with a
median of 70 (IQR 38–180) SFU/10
6 PBMCs among
infants born to HIV-negative mothers and a median of
73 (IQR 26–101) SFU/10
6 PBMCs among seroreverters.
More IFN-c-producing cells were present following
treatment with PPD or killed BCG than in negative control
cultures, indicated by positive SFUs, but these responses
were not inﬂuenced by maternal HIV status (Fig. 3).
HIV infection during pregnancy led to reduced
proliferative responses at 10 weeks
Functional T-cell memory was assessed at 10 weeks of age
by measuring speciﬁc proliferation in response to PPD
Table 1. Characteristics of human immunodeﬁciency virus (HIV)-negative infants born to HIV-negative and HIV-positive mothers
Characteristic
Infants born to HIV-negative
mothers Infants born to HIV-positive mothers
P Median IQR n Median IQR n
Birth weight (kg) 322 7–342 1 3 02 9–351 3 N S
Head circumference at birth (cm) 35 335–37 21 35 33–35 11 NS
Length at birth (cm) 47 45–51 21 46 45–49 11 NS
MUAC (cm) 1201 1 0–1382 01 0 01 0 0–1001 10 002
APGAR score at 1 min 8 8–9 21 8 7–9 13 NS
APGAR score at 5 min 10 10–10 21 10 10–10 13 NS
CD4 count at 2 weeks (%) 4624 2 5–5571 64 4 93 8 0–4861 2N S
CD4 count at 10 weeks (%) 4203 1 4–4631 03 0 72 6 0–3531 10 024
CD4 count at 2 weeks (10
6 cells/ml) 323 228–388 16 266 186–301 12 NS
CD4 count at 10 weeks (10
6 cells/ml) 261 232–304 10 198 173–275 11 0041
Comparisons were carried out by Mann–Whitney U-test.
IQR , interquartile range; MUAC, mid-upper arm circumference; NS, not signiﬁcant.
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tive control cultures appeared unaffected by maternal
HIV status, as the median numbers of divided CD4
T cells in the negative control treatments were 54% (IQR
32–87%) in infants with HIV-negative mothers and
54% (IQR 32–100%) in seroreverters, while median
numbers of divided CD8 T cells in the negative control
treatments were 50% (IQR 26–62%) in infants with
HIV-negative mothers and 30% (IQR 19–153%) in
seroreverters.
Antigen-speciﬁc division was calculated by subtracting
the percentage of divided cells in negative controls from
the percentage of divided cells in antigen-treated cultures.
Neither heat-killed BCG nor PPD stimulated much divi-
sion among CD8 T cells, as the percentage of divided cells
was < 5% in all cases. In CD4 T cells, heat-killed BCG
stimulated slightly more division but there was no dis-
cernable difference based on maternal HIV status, as the
median percentage of divided cells was 53% (IQR 11–
116%) in seroreverters and 42% (IQR 01–302%) in
infants with HIV-negative mothers. However, PPD
induced more division in the CD4 T cells of infants with
HIV-negative mothers (median 76%; IQR 08–280%)
than in those of seroreverters (median 56%; IQR 12–
114%), representing a 26% reduction in the percentage
of divided cells.
It was possible to carry out this assay on relatively few
infants as some had withdrawn from the study, and the
number of cells recoverable from 10-week-old infants was
often insufﬁcient to carry out the proliferation assay.
Nonetheless, a bimodal distribution was discernable in
proliferative responses to BCG and PPD, allowing infants
to be classiﬁed as high responders in which at least an
eighth of the cells remaining at the end of the culture per-
iod had divided, and low responders in which less than an
eighth had divided (Fig. 4). Few infants were classed as
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Figure 1. Maternal human immunodeﬁciency
virus (HIV) infection increases CD4 T-cell dif-
ferentiation in 10-week-old HIV-negative
infants. (a) CD45RA and CCR7 expression in
representative 10-week-old HIV-negative
infants with HIV-positive and HIV-negative
mothers, gated on CD4 T cells. (b) Concentra-
tions of CD4 T-cell subpopulations deﬁned by
CD45RA and CCR7 in 2- and 10-week-old
infants with HIV-positive and HIV-negative
mothers. (c) CD27 and CD28 expression in
representative 10-week-old HIV-negative
infants with HIV-positive and HIV-negative
mothers, gated on CD4 T cells. (d) Concentra-
tions of CD4 T-cell subpopulations deﬁned by
CD27 and CD28 in 2- and 10-week-old infants
with HIV-positive and HIV-negative mothers.
On composite plots, grey bars indicate medi-
ans. All statistical analysis was performed using
the Mann–Whitney U-test.
450   2009 Blackwell Publishing Ltd, Immunology, 129, 446–454
D. J. C. Miles et al.high responders based on their CD8 T-cell responses, but
when classiﬁed by CD4 T-cell responses to BCG, there
were more high responders among infants whose mothers
were HIV-uninfected (three of eight) than among serore-
verters (one of eight). There was a similar disparity in
responses to PPD between infants whose mothers were
HIV-uninfected (ﬁve of 10) and seroreverters (one of 10).
Maternal HIV status did not affect maternal antibody
transfer or infant antibody responses
To assess the inﬂuence of HIV in pregnancy on antibody
levels, we assessed levels of both anti-M. tuberculosis and
anti-polio IgG at 10 weeks, controlled for levels in umbili-
cal cord blood. There were no signiﬁcant differences either
in the umbilical cord blood or infant blood at 10 weeks.
Median anti-M. tuberculosis IgG at 10 weeks was 1964
(IQR 1063–2639) U/ml in infants with HIV-negative
mothers and 1580 (IQR 492–2249) U/ml in sero-
reverters, and median levels of anti-polio IgG were 164
(IQR 107–197) IU/ml in infants with HIV-negative
mothers and 143 (IQR 051–177) IU/ml in seroreverters.
Discussion
Childhood responses are inﬂuenced by a number of
factors that affect pregnancy. Many, such as poor
nutrition
30–33 and malaria,
34 are highly prevalent in Sub-
Saharan Africa. HIV infection during pregnancy has also
been shown to have a profound and long-lasting effect on
childhood immune responses.
3
We found that, by 10 weeks, the CD4 count of sero-
reverters had dropped to levels characteristic of HIV-posi-
tive African infants of equivalent age and well below those
typical of HIV-negative infants.
35 The phenotypic differ-
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Figure 2. Maternal human immunodeﬁciency virus (HIV) infection leads to a higher proportion of CD4 T cells expressing markers of senescence
in 10-week-old HIV-negative infants. (a) Representative CD57 and CD27 expression by CD4 T cells of 10-week-old HIV-negative infants with
HIV-positive and HIV-negative mothers. Percentages of CD4 T cells expressing CD57 are given. (b) Percentage of CD4 T cells expressing CD57
at 2 and 10 weeks of age in HIV-negative infants born to HIV-negative and HIV-positive mothers. Bars indicate medians. (c) PD-1 and CD27
expression by the CD4 T-cells of HIV-negative infants with HIV-positive and HIV-negative mothers. Percentages of total CD4 T cells expressing
PD-1 are given. (d) Percentage of CD4 T cells expressing PD-1 at 2 and 10 weeks of age in HIV-negative infants born to HIV-negative and HIV-
positive mothers. Bars indicate medians. All statistical comparisons were by Mann–Whitney U-test.
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Figure 3. Maternal human immunodeﬁciency virus (HIV) status has
no discernable effect on interferon (IFN)-c release in 2-week-old
infants. The peripheral blood mononuclear cells (PBMCs) of 2-week-
old infants were stimulated with (a) heat-killed Bacille Calmette-
Gue ´rin (BCG) or (b) puriﬁed protein derivative (PPD) and IFN-c
responses measured by enzyme-linked immunosorbent spot-forming
cell assay (ELISpot) after 18 hr. Values are expressed as negative con-
trol subtracted from treatment, so cases where proliferation was
greater in the negative control return negative values.
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had come from early and undifferentiated cells, identiﬁed
by expression of CCR7 and CD27,
25,36 while higher propor-
tions of CD4 T cells expressed CD57 and PD-1, which are
associated with poor replication and function.
26–28 While
the same changes in the CD4 T-cell compartment are asso-
ciated with progressive HIV infection,
27,37,38 similar
changes are associated with the aging of healthy
adults,
11,12,39 implying that they are indicative of general
immune activation rather than a speciﬁc response to HIV.
The central memory T-cell population that proliferates
in response to antigen is characterized by the CCR7
+
CD45RA
) phenotype;
40 hence the smaller central memory
subpopulation of seroreverters at 10 weeks was associated
with a bimodal proliferative response to PPD with some
high responders and some low responders. The differences
in central memory subpopulation size appeared between 2
and 10 weeks, suggesting that the subpopulation struc-
ture at the time of ﬁrst exposure to the antigen was less
important to the magnitude of the recall response than the
subpopulation structure at the time of re-exposure.
The greater importance of central memory subpopula-
tion size at the time of re-exposure than at ﬁrst exposure
is supported by evidence from a previous study on prolif-
erative responses to the measles vaccine.
21 There, central
memory subpopulation size differed between treatments
at the time of vaccination but not by the time of re-expo-
sure, and proliferative responses following re-exposure
were also similar between the treatment groups. Loss of
CCR7 is associated with a shortening of telomeres and
loss of proliferative capacity,
40 so it is likely that the cen-
tral memory cells are the precursors for proliferation and
the ability of seroreverters to mount a strong proliferative
response is lost with them.
Our results beg the question of how HIV in pregnancy
can affect the development of the immune system without
actually infecting the infant. All infants were healthy at
birth, which rules out the possible inﬂuence of preterm
birth or intrauterine growth retardation. One possibility is
that the infant responses are inﬂuenced by HIV antigens
crossing the placenta, either in solution or during an
infection that is later cleared. HIV-speciﬁc T-cell responses
in seroreverters have been widely reported, as reviewed by
Kuhn et al.,
41 and, although there is considerable variation
in the assay methods and frequency of responding infants,
stimulation with peptide pools derived from the gag, env
and nef HIV proteins induced detectable responses in
90–100% of tested infants.
3,42 This suggests that prenatal
or possibly perinatal exposure to HIV antigens is common
enough to account for the almost ubiquitous effects that
we observed. However, it remains to be established
whether exposure to HIV antigens without infection can
exert such a powerful inﬂuence.
Another possibility is that the inﬂuence on the infant
immune system is not derived directly from HIV contact
but from exposure to a maternal immune system under
the inﬂuence of HIV, which induces considerable acti-
vation and differentiation among both CD4 and CD8
T cells.
10,23,26-28,43,44 This reprogramming is likely to dra-
matically affect the milieu of cytokines and chemokines
present in maternal blood and lymphoid systems. Although
we are aware of no direct evidence for vertical transfer of
cytokines and chemokines to the fetal circulation, maternal
cells have been detected in fetal blood in around 40% of
healthy pregnancies,
45 demonstrating that transplacental
trafﬁc is commonplace. Transplacental transfer of activa-
ting cytokines would directly expose the immune system of
the fetus to an immunological environment conducive to
differentiation. This is the subject of current investigations.
Although polyclonally induced IFN-c and IL-12 pro-
duction has been shown to be reduced in the umbilical
cord blood cells of seroreverters,
13 we found that, at
2 weeks, there was little or no effect of HIV in pregnancy
on differentiation or the effector phase of the immune
response to BCG. Taken together, these ﬁndings suggest
that seroreverters’ immune systems are impaired at birth,
but that the extent of the impairment increases during
the ﬁrst weeks of life until the generalized effects that we
observed at 10 weeks become apparent.
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Figure 4. Maternal human immunodeﬁciency virus (HIV) infection
leads to a reduced antigen-speciﬁc proliferation in 10-week-old HIV-
negative infants. Plots indicate percentages of divided CD4 T cells,
measured by carboxyﬂuorescein diacetate succinimidyl ester (CFSE)
dilution, following 8 days of culture after stimulation with (a) puri-
ﬁed protein derivative (PPD) and (b) Bacille Calmette-Gue ´rin
(BCG), and percentages of divided CD8 T cells after stimulation with
(c) PPD and (d) BCG. The dashed line indicates delineation of high-
level responders. Values are expressed as negative control subtracted
from treatment, so cases where proliferation was greater in the nega-
tive control return negative values.
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sufﬁcient to repeat the assay for overnight IFN-c produc-
tion at 10 weeks, but the CD4 T cells were more differenti-
ated and appeared less able to respond to BCG in the
seroreverters. The implication is that either the mechanism
behind immune impairment is initiated late in pregnancy,
or that the increased levels of regulation induced by HIV
infection
46 counter the stimulatory inﬂuences during preg-
nancy but wane faster after birth. In either case, we suggest
that the reported effects on umbilical cord blood cytokine
production are merely the ﬁrst hints of a process that is far
from complete by 2 weeks after birth.
The scope of the ﬁndings of this study is limited by
several factors. Firstly, although we tried to restrict recruit-
ment to infants with healthy birth weights in order to
exclude confounding with the prenatal undernutrition
often associated with HIV in pregnancy,
4,5,47 the lower
MUACs of seroreverters indicated slightly poorer nutrition
during pregnancy. Secondly, the possible inﬂuence of nevi-
rapine treatment could not be assessed as it was unethical
to deny treatment to any HIV-positive mother–infant pairs
or to administer it in the absence of HIV infection. Nevira-
pine has been associated with slight immune activation at
birth, in the form of elevated levels of neopterin and sL-
selectin in umbilical cord blood serum,
48 but its longer
term effects on the development of the immune system
have not been assessed. Finally, the low volumes of blood
available limited our ability to provide detailed insights
into CD4 phenotype and CD8-mediated immune memory.
In conclusion, given the importance of CD4 T cells in
protection against tuberculosis,
49–51 it is of concern that
the large number of infants born to HIV-positive mothers
in Africa may have impaired CD4 T-cell responses and
increased vulnerability to tuberculosis and possibly a
range of other infections, especially in the light of the evi-
dence that immune deﬁciencies in such infants may last
for several years.
3,13 It is of particular interest to know
whether the levels of CD4 T-cell differentiation continue
to rise, stabilize or recover after 10 weeks, and whether
antigen-speciﬁc proliferative responses follow the trend
set by the differentiation. A number of strategies to
improve protection of seroreverters may be possible, such
as boosting the vaccine later in infancy, or using novel
delivery systems that may not be appropriate for general
use, but may be considered for a high-risk group that is
often identiﬁed by antenatal HIV testing.
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